aTyr’s primary focus is ATYR1923, a clinical-stage product candidate, which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases . . .
It’s a tRNA World: How aTyr Transformed tRNA Synthetases into Clinical Stage Medicines
These enzymatic staples of classroom biology represent a novel set of physiological modulators with clinical potential
[Source: aTyr Pharma]
